Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.36 |
| ▸ | APOL1 | O14791 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26087612 | 1.00 | CRBN (0.36) | CRBNAPOL1DDB1POLB | |
| SCHEMBL26089796 | 0.96 | EPHX1 (0.37) | CRBNAPOL1DDB1POLB | |
| SCHEMBL26437058 | 0.96 | EPHX1 (0.37) | CRBNAPOL1DDB1POLB | |
| SCHEMBL26088940 | 0.95 | EPHX1 (0.39) | CRBNAPOL1DDB1 | |
| SCHEMBL26436847 | 0.95 | EPHX1 (0.39) | CRBNAPOL1DDB1 | |
| SCHEMBL30407877 | 0.95 | EPHX1 (0.39) | CRBNAPOL1DDB1 | |
| SCHEMBL30407697 | 0.94 | CRBN (0.34) | CRBNAPOL1DDB1POLB | |
| SCHEMBL26437145 | 0.93 | CRBN (0.35) | CRBNAPOL1DDB1 | |
| SCHEMBL26089045 | 0.93 | CRBN (0.34) | CRBNDDB1 | |
| SCHEMBL26437147 | 0.93 | CRBN (0.34) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | CRBN 1/4885APOL1 2860/4885DDB1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.